Newsquawk Daily US Earnings Estimates - 30th October 2026: CVX, XOM, GD, ABBV

This report is a detailed calendar of all earnings for the stocks in the S&P 500, DJIA, Nasdaq 100 and other significant companies.

This is a pre-open calendar of expected earnings rather than a result, so the note is the slate itself: a cluster heavy on integrated energy (CVX, XOM), large-cap pharma (ABBV, REGN), defence (GD) and staples (CL, CHD, KVUE), all reporting before the cash open. Sessions where both US supermajors print on the same morning have historically set the tone for the energy complex, with the upstream/downstream mix and capital return commentary in one name quickly read across to the other and to the European majors, and any signal on buyback pace or capex discipline tending to move the group rather than the single stock. ABBV and REGN together make the session a two-sided test of large-cap biotech sentiment, where the established pattern is that guidance and key franchise commentary outweigh the quarterly beat or miss, particularly around maturing products facing competitive or pricing pressure. Defence names like GD print against a backdrop of order backlogs and budget flows, and the sector has typically traded on book-to-bill and margin trajectory rather than headline EPS. The staples and utilities on the slate are usually low-beta affairs unless guidance breaks trend, but clustered consumer prints have on past occasions collectively shifted the defensives versus cyclicals debate. The follow-ons are the conference calls, where full-year outlook revisions, not the quarter itself, have historically driven the durable move.